Floatz logo

Bms-907351

Fumarate Hydratase (FH)-Deficient Tumors

Calithera Biosciences, IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Fumarate Hydratase (FH)-Deficient Tumors cohort.

Asset / SponsorPhaseRating
Axitinib
West China Hospital
Phase 2CCC
Telaglenastat
Calithera Biosciences, Inc
Phase 1CC
Cbe
Calithera Biosciences, Inc
Phase 1CC
ACETIC-1-13C ACID
University of Texas Southwestern Medical Center
N/AD
GLUCOSE, ANHYDROUS
University of Texas Southwestern Medical Center
N/AD
Lactate
University of Texas Southwestern Medical Center
N/AD
Glutamine
University of Texas Southwestern Medical Center
N/AD
13C-Fructose
University of Texas Southwestern Medical Center
N/AD

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →